Gilead Sciences (NASDAQ: GILD) approached Forty Se
Post# of 145746
![Avatar](/images/ProfileImages/167738657_59587_mando klein.jpg)
Interesting...
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Forty Seven’s lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)